A Multicenter, Retrospective Study (RE-ENACT 2) on the Use of Razumab™ (World’s First Biosimilar Ranibizumab) in Wet Age-Related Macular Degeneration

INTRODUCTION: The REal life assessmENt of safety And effeCTiveness of Razumab (RE-ENACT) and long-term RE-ENACT 2 retrospective studies have evaluated the use of Razumab™ (world’s first biosimilar ranibizumab) in retinal disorders in Indian patients. This report presents the subgroup analysis from t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Shashikant, Khan, Mujtaba, Chaturvedi, Alok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054591/
https://www.ncbi.nlm.nih.gov/pubmed/31883056
http://dx.doi.org/10.1007/s40123-019-00228-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054591/
https://www.ncbi.nlm.nih.gov/pubmed/31883056
http://dx.doi.org/10.1007/s40123-019-00228-7

Ejemplares similares